Tech Company Financing Transactions

Rivus Pharmaceuticals Funding Round

On 7/22/2021, Rivus Pharmaceuticals raised $35 million in Series A investment from Longitude Capital Management, Medicxi Ventures and RxCelerate.

Transaction Overview

Company Name
Rivus Pharmaceuticals
Announced On
7/22/2021
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series A
Investors

Longitude Capital Management (Lead Investor) (Patrick Enright)

Medicxi Ventures (Lead Investor) (David Grainger)

RxCelerate (Lead Investor)

Proceeds Purpose
The Series A financing will enable Rivus to advance a pipeline of CMA therapies to treat a range of metabolic conditions including type 2 diabetes, severe hypertriglyceridemia (SHTG), non-alcoholic steatohepatitis (NASH), as well as cardiovascular diseases such as heart failure with preserved ejection fraction (HFpEF).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
706 B Forest St.
Charlottesville, VA 22903
USA
Phone
Undisclosed
Website
www.rivuspharma.com
Email Address
[email protected]
Overview
Rivus Pharmaceuticals is dedicated to improving cardio-metabolic health by developing controlled metabolic accelerators (CMAs) that address the underlying metabolic risk factors for cardiovascular mortality and morbidity.
Profile
Rivus Pharmaceuticals LinkedIn Company Profile
Social Media
Rivus Pharmaceuticals Company Twitter Account
Company News
Rivus Pharmaceuticals News
Facebook
Rivus Pharmaceuticals on Facebook
YouTube
Rivus Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Allen Cunningham
  Allen Cunningham LinkedIn Profile  Allen Cunningham Twitter Account  Allen Cunningham News  Allen Cunningham on Facebook
Chief Scientific Officer
Shaharyar Khan
  Shaharyar Khan LinkedIn Profile  Shaharyar Khan Twitter Account  Shaharyar Khan News  Shaharyar Khan on Facebook
Vice President
Francisco Portell
  Francisco Portell LinkedIn Profile  Francisco Portell Twitter Account  Francisco Portell News  Francisco Portell on Facebook

 

 

Browse more venture capital transactions:

Prev: 7/22/2021: FloQast venture capital transaction
Next: 7/22/2021: Dwolla venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.